Omeros Corp

This non-binding management proposal asks shareholders to approve, on an annual advisory basis, the company’s executive compensation as disclosed in the proxy (the CD&A, compensation tables and narrative). Management seeks this endorsement to gauge shareholder support for its compensation policies and practices while retaining discretion over actual pay decisions; the board and compensation committee will consider the vote results when making future decisions. The context includes 2025 corporate milestones—FDA approval of YARTEMLEA, the sale of zaltenibart to Novo Nordisk, balance sheet strengthening and discrete 2025 compensation actions (base salary adjustments, cash bonuses and substantial stock option grants)—all of which management cites when defending its program. The proposal is explicitly non-binding and will not compel changes, but a strong vote against could trigger additional shareholder engagement and potential adjustments by the compensation committee. The board recommends a FOR vote, arguing that compensation aligns executives’ interests with shareholders through a mix of base pay, performance-based cash bonuses and long-term equity incentives and that pay decisions are grounded in competitive benchmarking and retention needs. From a governance perspective, investors should weigh the program’s alignment with performance, the magnitude and structure of equity grants (notably large option awards in 2025), and the company’s rationale that recent operational and strategic successes justify their compensation decisions. The board highlights past high shareholder support (89% in 2025) as evidence of alignment, but investors should still consider dilution risk from option grants and how future milestones will be tied to pay. Ultimately, the vote is a signal to the board rather than a directive, but it materially influences compensation committee actions and investor relations.

Management is asking shareholders to approve an amended and restated omnibus equity incentive plan that increases the share reserve by 6 million shares (to 23.6 million) and extends the plan term by ten years. Management frames the request as necessary to attract, retain and motivate employees and directors—especially given anticipated commercial buildout after FDA approval of YARTEMLEA and strategic transactions like the sale of zaltenibart—so that Omeros can continue to grant competitive equity awards. The amended plan preserves key protections for shareholders (anti-repricing without shareholder approval, limitations on share recycling, and clawback compliance) while adding governance-aligned features such as a fungible share design (full-value awards count as 1.5 shares) and explicit clawback language. The board argues the increase is time- and headcount-driven: recent and expected hiring for commercial and R&D functions will require additional equity, including senior-level awards that are more share-intensive. From a shareholder perspective, the trade-offs are conventional: the plan supports compensation and retention but increases potential dilution; investors should consider the company’s historical grant cadence, current outstanding options (~15.6 million as of March 31, 2026), and available reserve (about 3.9 million before the requested increase). The board’s recommendation emphasizes stewardship—limiting repricing, disallowing recycling of shares used for tax withholding or repurchases with option proceeds, and requiring shareholder approval for certain actions—intended to mitigate dilution and governance risks. Analysts should scrutinize expected burn rate, the mix between option and full-value awards (1.5 fungibility factor), and whether performance-based vehicles will be meaningfully used to align pay with outcomes. If approved, the plan maintains broad administrative discretion (e.g., award types, vesting, change-in-control treatment) which is typical but requires active board/committee oversight to ensure alignment with shareholder value creation.